Sonara Health Granted Patent For Take-Home Methadone Monitoring System

Revolutionary Monitoring System's Tamper-Evident Label Allows People To More Safely Consume Methadone From Home, Eliminating Daily Clinic Visits

What To Know

  • “In a world where we send billionaires to space in reusable rockets, I thought we ought to be able to create a solution that helps patients with opioid use disorder to get their daily medication in a way that does not disrupt their daily lives, all while preserving the safety and efficacy of a proven delivery system,”.
  • The phone’s camera then turns on and a video stream of the patient drinking the methadone is uploaded to the clinician-facing application for the care team to review and ensure proper medication handling.

Sonara Health has been granted a U.S. patent for creating a tamper-evident label that facilitates the safe consumption of methadone at home to treat opioid use disorder and fight America’s opioid crisis.

Sonara Health’s remote medication monitoring system includes a tamper-evident label, a patient-facing web application to guide the patient’s daily consumption of methadone at home and a clinician-facing web application to remotely, asynchronously, observe patients dosing. The Sonara remote medication monitoring system helps eliminate the need for patients to visit a clinic every day, which is often a barrier for people who live far away from clinics or who have jobs and family obligations.

Methadone is among the most effective medications approved by the FDA to treat opioid use disorder.

“In a world where we send billionaires to space in reusable rockets, I thought we ought to be able to create a solution that helps patients with opioid use disorder to get their daily medication in a way that does not disrupt their daily lives, all while preserving the safety and efficacy of a proven delivery system,” said Michael Giles, M.D., and CEO of Sonara Health.

The Mark Cuban-backed health-tech company was designed to improve patient-provider trust and promote access to take-home methadone for opioid treatment programs and their patients. Sonara’s mission is to end the opioid epidemic. Staggering data from the CDC showed over 100,000 people died from drug overdoses last year and about two-thirds of those deaths involved fentanyl or another synthetic opioid.

The Sonara medication monitoring system is simple. The patient scans the QR code on the methadone bottle with their smartphone and follows the steps provided for dosing-at-home. Once scanned and opened, the QR code is voided and the label indicates that it has been opened. The phone’s camera then turns on and a video stream of the patient drinking the methadone is uploaded to the clinician-facing application for the care team to review and ensure proper medication handling.

Early adopters of Sonara include the following opioid treatment programs:

BayMark Health Services, Inc.

BAART, Market Street, San Francisco, CA
BAART, Norwood, Sacramento, CA
HCRC, New Bedford, MA
RSONM, Five Points, Albuquerque, NM (coming soon)
RSONM, Roswell, NM (coming soon)
CODA, Inc.

CODA, Portland, OR
CODA, Seaside, OR
New Season Treatment Centers

Augusta Metro Treatment Center, Augusta, GA

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy